Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
既往治疗作为接受 [(177)Lu]Lu-PSMA-617 治疗的转移性去势抵抗性前列腺癌患者总生存期的预后因素。一项 WARMTH 多中心研究（617 试验）
期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-020-04797-9
Ahmadzadehfar, Hojjat; Rahbar, Kambiz; Baum, Richard P; Seifert, Robert; Kessel, Katharina; Bögemann, Martin; Kulkarni, Harshad R; Zhang, Jingjing; Gerke, Carolin; Fimmers, Rolf; Kratochwil, Clemens; Rathke, Hendrik; Ilhan, Harun; Maffey-Steffan, Johanna; Sathekge, Mike; Kabasakal, Levent; Garcia-Perez, Francisco Osvaldo; Kairemo, Kalevi; Maharaj, Masha; Paez, Diana; Virgolini, Irene
